Table 3.
Follow-up measurements
| Baseline |
1 day |
6 days |
14 days |
3 months |
12 months |
P-value | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | AdVEGF-D | Control | AdVEGF-D | Control | AdVEGF-D | Control | AdVEGF-D | Control | AdVEGF-D | Control | AdVEGF-D | ||
| n = 6 | n = 6 | n = 6 | n = 6 | n = 6 | |||||||||
| n = 24 | |||||||||||||
| n = 24 | |||||||||||||
| n = 6 | n = 24 | ||||||||||||
| n = 24 | n = 24 | ||||||||||||
| n = 24 | |||||||||||||
| B-Hb (g/L) | 143 ± 15 | 141 ± 16 | 138 ± 14 | 136 ± 16 | 137 ± 19 | 138 ± 14 | 135 ± 18 | 137 ± 15 | 142 ± 17 | 141 ± 15 | 145 ± 18 | 142 ± 18 | 0.011 |
| B-Leuc (×109/L) | 8.4 ± 2.6 | 6.6 ± 1.4 | 7.8 ± 1.7 | 7.0 ± 1.5 | 7.2 ± 1.5 | 7.6 ± 4.0 | 6.9 ± 1.2 | 6.1 ± 1.1 | 7.9 ± 2.1 | 6.9 ± 1.2 | 8.6 ± 2.8 | 7.0 ± 1.2 | 0.569 |
| B-Thromb (×109/L) | 274 ± 70 | 214 ± 63 | 247 ± 53 | 186 ± 61 | 289 ± 38 | 218 ± 75 | 269 ± 29 | 229 ± 72 | 247 ± 61 | 201 ± 59 | 261 ± 58 | 205 ± 86 | 0.001 |
| P-Alt (U/L) | 34 ± 17 | 32 ± 28 | NA | NA | 39 ± 20 | 30 ± 17 | 31 ± 13 | 30 ± 15 | 32 ± 24 | 29 ± 15 | 34 ± 16 | 26 ± 11 | 0.277 |
| P-CRP (mg/l) | 4 ± 2 | 4 ± 2 | 6 ± 3 | 9 ± 8 | 5 ± 3 | 13 ± 29 | 3 ± 0 | 4 ± 3 | 4 ± 2 | 3 ± 0 | 5 ± 3 | 3 ± 0 | 0.022 |
| P-Tnt (ng/L) | 10 ± 4 | 14 ± 6 | 95 ± 56 | 93 ± 39 | 12 ± 2 | 21 ± 17 | 11 ± 5 | 16 ± 8 | 14 ± 4 | 16 ± 9 | 14 ± 6 | 14 ± 9 | 0.001 |
| Systolic BP (mmHg) | 158 ± 16 | 141 ± 20 | 134 ± 25 | 131 ± 16 | NA | NA | NA | NA | 151 ± 21 | 141 ± 22 | 148 ± 21 | 140 ± 20 | 0.886 |
| Diastolic BP (mmHg) | 88 ± 10 | 80 ± 13 | 74 ± 12 | 71 ± 15 | NA | NA | NA | NA | 83 ± 11 | 76 ± 13 | 82 ± 21 | 76 ± 13 | 0.018 |
| CCS class | 2.67 ± 0.52 | 2.83 ± 0.38 | NA | NA | NA | NA | NA | NA | 2.17 ± 0.75 | 2.43 ± 0.59 | 2.00 ± 0.71 | 2.11 ± 0.47 | 0.001 |
Mean ± SD. P-value for interaction time x group. P-values for all comparisons in Supplementary material online, Table S1.
TnT, Troponine-T, BNP, N-terminal pro-brain natriuretic peptide; CCS, Canadian Cardiovascular Society class.